Nurexone Biologic Inc
F:J90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nurexone Biologic Inc
PP&E Net
Nurexone Biologic Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
PP&E Net
$102k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Enerflex Ltd
TSX:EFX
|
PP&E Net
CA$849m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
PP&E Net
CA$531m
|
CAGR 3-Years
41%
|
CAGR 5-Years
38%
|
CAGR 10-Years
26%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
PP&E Net
CA$487.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Secure Energy Services Inc
TSX:SES
|
PP&E Net
CA$1.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
PP&E Net
$1.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
145%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's PP&E Net?
PP&E Net
102k
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's PP&E Net amounts to 102k USD.
What is Nurexone Biologic Inc's PP&E Net growth rate?
PP&E Net CAGR 1Y
0%
Over the last year, the PP&E Net growth was 0%.
